diff --git a/cases.html b/cases.html index 17b3dce..79283ce 100644 --- a/cases.html +++ b/cases.html @@ -78,10 +78,11 @@
- Under development + Replimune is a biotechnology startup developing oncolytic viruses as immunotherapies. These engineered viruses, derived from herpes simplex virus type 1, are designed to activate local and systemic immune response against cancers. Combinations with checkpoint blockade have demonstrated potent tumor response. The company is managed by those who led efforts in developing and commercializing talimogene laherparepvec (T-Vec), the first oncolytic virus approved by the FDA.